Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Fibroblast for Nasolabial Folds
NCT03140319Phase 2Unknown
- Sponsor
- SCARM Institute
- Start
- Dec 2020
- Primary completion
- Nov 2021
- Modality
- Bone Marrow HSCs, Peripheral Blood HSCs
- Countries
- 1
01
Overview
Phase 2, randomised trial of azficel-t in nasolabial folds and Skin aging (2 arms), sponsored by SCARM Institute. Primary endpoint: Correction of Nasolabial at 6 months. Status: unknown.
02
Drugs
azficel-t
03
Conditions
nasolabial foldsSkin aging
Beyond the preview
Go deeper on NCT03140319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03140319.